Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00163137 · ClinicalTrials.gov registry record · Phase 3
Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss
A Phase 3 study, sponsored by Ligand Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 540
- Enrollment target
NCT00163137: Completed Phase 3 study, sponsored by Ligand Pharmaceuticals.
NCT00163137 is a Phase 3 study that has completed, run by Ligand Pharmaceuticals. The registered enrollment target is 540 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (30% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00163137, a Phase 3 study, has completed, sponsored by Ligand Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 540 participants
- Enrollment target
Study Summary
To compare the effects of 2 years of lasofoxifene treatment with 2 years of raloxifene 60 mg/day use and 2 years of placebo use on bone mineral density (BMD) of the lumbar spine.
Primary Outcome
Lumbar Spine Bome Mineral Density
Interventions
- DRUG Placebo
- DRUG raloxifene
- DRUG lasofoxifene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 540 participants |
| Start Date | 2003-05 |
| Est. Completion | 2005-10 |
| Phase | Phase 3 |
What the finished NCT00163137 record still lists
NCT00163137 is an interventional study that assigns participants to a tested intervention. The registered 540 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (30% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00163137 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00163137 about?
NCT00163137 is a clinical study titled "Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss". To compare the effects of 2 years of lasofoxifene treatment with 2 years of raloxifene 60 mg/day use and 2 years of placebo use on bone mineral density (BMD) of the lumbar spine.
What is the current status of trial NCT00163137?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 540 participants. The study started on 2003-05. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00163137?
The interventions under investigation include: Placebo (DRUG), raloxifene (DRUG), lasofoxifene (DRUG).
Who is sponsoring clinical trial NCT00163137?
This trial is sponsored by Ligand Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00163137's enrollment target sits among peer trials
540 694th of 2000 higher than 1,301 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04557462 · 540 participants · Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
- NCT04956640 · 540 participants · Phase 1
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
- NCT05429892 · 540 participants · NA
FRESH Delivers: An Innovative Approach to Reducing Tobacco Use Among Rural Smokers
- NCT05549297 · 540 participants · Phase 3
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia